

Mahesh K B Parmar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7260248/publications.pdf>

Version: 2024-02-01

86
papers

18,149
citations

66315

42
h-index

58549

82
g-index

88
all docs

88
docs citations

88
times ranked

19157
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 110-118.	1.1	2
2	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). <i>Clinical Trials</i> , 2022, 19, 52-61.	0.7	16
3	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	0.8	40
4	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. <i>Clinical Trials</i> , 2022, 19, 146-157.	0.7	7
5	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	6.3	173
6	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1772-1782.	0.8	9
7	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, 754-764.	1.5	4
8	Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials. <i>BMJ Open</i> , 2022, 12, e055615.	0.8	8
9	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	2.3	29
10	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 730-739.	2.5	10
11	090... Clinical trials in amyotrophic lateral sclerosis: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A40.1-A40.	0.9	0
12	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.	1.1	4
13	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	3.9	35
14	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. <i>BMJ Open</i> , 2022, 12, e064173.	0.8	10
15	A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. <i>PLoS Medicine</i> , 2021, 18, e1003629.	3.9	21
16	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology, The</i> , 2021, 22, 727-736.	5.1	45
17	Accessing routinely collected health data to improve clinical trials: recent experience of access. <i>Trials</i> , 2021, 22, 340.	0.7	16
18	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 2182-2193.	6.3	313

#	ARTICLE	IF	CITATIONS
19	Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. <i>Journal of Clinical Oncology</i> , 2021, 39, 3705-3715.	0.8	51
20	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3693-3704.	0.8	19
21	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021, 108, 106481.	0.8	2
22	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482.	0.8	33
23	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. <i>Brain Communications</i> , 2021, 3, fcab242.	1.5	32
24	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4075.	0.8	78
25	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	6.3	226
26	Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. <i>Lancet, The</i> , 2020, 396, 1422-1431.	6.3	224
27	Predictive classifier for intensive treatment of head and neck cancer. <i>Cancer</i> , 2020, 126, 5263-5273.	2.0	11
28	Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer. <i>Journal of Parkinson's Disease</i> , 2020, 10, 413-428.	1.5	15
29	Adding new experimental arms to randomised clinical trials: Impact on error rates. <i>Clinical Trials</i> , 2020, 17, 273-284.	0.7	25
30	Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study. <i>PLoS Medicine</i> , 2020, 17, e1003019.	3.9	48
31	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 2020, 9, 1109.	0.8	8
32	Abiraterone in High- and Low-risk Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	0.9	142
33	Mind the gap? The platform trial as a working environment. <i>Trials</i> , 2019, 20, 297.	0.7	28
34	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019, 20, 264.	0.7	42
35	Comments on design and monitoring of survival trials in complex scenarios. <i>Statistics in Medicine</i> , 2019, 38, 2704-2704.	0.8	0
36	Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. <i>Trials</i> , 2019, 20, 294.	0.7	37

#	ARTICLE	IF	CITATIONS
37	Combined test versus logrank/Cox test in 50 randomised trials. <i>Trials</i> , 2019, 20, 172.	0.7	17
38	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GClG phase 3 randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 2084-2095.	6.3	142
39	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	2.6	19
40	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	6.3	901
41	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , 2018, 24, 4726-4733.	3.2	39
42	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	1.3	70
43	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	13.9	1,315
44	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017, 14, 451-461.	0.7	59
45	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 84, 88-101.	1.3	128
46	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2017, 7, e011822.	0.8	8
47	Quality of life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (<sc>PATCH</sc>) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. <i>BJU International</i> , 2017, 119, 667-675.	1.3	34
48	Cancer Drugs Fund requires further reform. <i>BMJ, The</i> , 2016, 354, i5090.	3.0	26
49	Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes. <i>Trials</i> , 2016, 17, 309.	0.7	16
50	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 387, 1066-1074.	6.3	216
51	STAMPEDE trial and patients with non-metastatic prostate cancer – Authors' reply. <i>Lancet, The</i> , 2016, 388, 235-236.	6.3	6
52	Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. <i>BMC Medical Research Methodology</i> , 2016, 16, 16.	1.4	51
53	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 945-956.	6.3	791
54	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	6.3	1,570

#	ARTICLE	IF	CITATIONS
55	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology, The</i> , 2016, 17, 243-256.	5.1	361
56	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 348.	3.4	155
57	Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2016, 34, 162-162.	0.8	6
58	Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKTOCS.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5507-5507.	0.8	0
59	Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data. <i>Statistics in Medicine</i> , 2015, 34, 2881-2898.	0.8	51
60	Comments on "A modest proposal for dropping poor arms in clinical trials" by Proschan and Dodd. <i>Statistics in Medicine</i> , 2015, 34, 2678-2679.	0.8	1
61	Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , 2015, 386, 249-257.	6.3	1,042
62	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015, 67, 1028-1038.	0.9	340
63	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2143-2150.	0.8	213
64	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Journal of Clinical Oncology</i> , 2015, 33, 2062-2071.	0.8	166
65	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	0.9	56
66	More multiarm randomised trials of superiority are needed. <i>Lancet, The</i> , 2014, 384, 283-284.	6.3	105
67	An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect. <i>Trials</i> , 2014, 15, 314.	0.7	29
68	Evaluating Many Treatments and Biomarkers in Oncology: A New Design. <i>Journal of Clinical Oncology</i> , 2013, 31, 4562-4568.	0.8	128
69	Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). <i>Lancet Oncology, The</i> , 2013, 14, 306-316.	5.1	83
70	Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. <i>BMC Medical Research Methodology</i> , 2013, 13, 152.	1.4	605
71	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012, 13, 168.	0.7	121
72	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , 2011, 12, 61.	0.7	40

#	ARTICLE	IF	CITATIONS
73	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. <i>Lancet Oncology, The</i> , 2011, 12, 38-48.	5.1	176
74	Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. <i>Trials</i> , 2011, 12, 81.	0.7	49
75	Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , 2011, 12, .	0.7	10
76	The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. <i>Statistics in Medicine</i> , 2011, 30, 2409-2421.	0.8	363
77	Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. <i>Trials</i> , 2009, 10, 39.	0.7	120
78	Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. <i>BJU International</i> , 2009, 103, 464-469.	1.3	86
79	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology, The</i> , 2009, 10, 327-340.	5.1	738
80	Speeding up the Evaluation of New Agents in Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1204-1214.	3.0	126
81	Recruitment to multicentre trials—lessons from UKCTOCS: descriptive study. <i>BMJ: British Medical Journal</i> , 2008, 337, a2079-a2079.	2.4	128
82	Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. <i>Statistics in Medicine</i> , 2003, 22, 2239-2256.	0.8	128
83	Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. <i>Statistics in Medicine</i> , 2002, 21, 2175-2197.	0.8	1,062
84	Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. <i>Statistics in Medicine</i> , 1998, 17, 2815-2834.	0.8	4,325
85	Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (oesophageal cancer collaborative group). <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 579-583.	0.4	157
86	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 0, 9, 1109.	0.8	7